BY Fraser Tennant
In the largest acquisition in its history, Italy’s family-owned Chiesi Group is to buy its peer – global pharmaceutical company KalVista Pharmaceuticals – in an all-cash deal valued at $1.9bn.
Under the terms of the definitive agreement – which is not subject to any financing condition – Chiesi will acquire all outstanding shares of KalVista for $27 per share in cash, representing a 36 percent premium to KalVista’s 30-day volume-weighted average share price as of 28 April 2026.
Upon completion of the transaction, Chiesi will assume responsibility for sebetralstat, a differentiated oral, on‑demand treatment for hereditary angioedema (HAE), developed by KalVista, which addresses a significant unmet need for patients requiring effective and accessible therapies.
In line with Chiesi’s mission and strategic objectives, Sebetralstat is also expected to meaningfully contribute to Chiesi’s 2030 strategic revenue target of €6bn, while significantly expanding its commercial infrastructure and market presence in the US.
“This acquisition is a strong strategic fit for our rare disease portfolio and reflects our commitment to people living with rare conditions,” said Giacomo Chiesi, executive vice president, global rare diseases at Chiesi. “In HAE, patients continue to face significant unmet needs, and KalVista’s innovation meaningfully expands our presence in rare immunology by adding a differentiated, on-demand treatment option that can bring meaningful advancement in how the disease can be managed.”
By combining KalVista’s innovation with Chiesi’s global rare diseases capabilities in rare immunology, the transaction aims to accelerate patient access and strengthen medical and scientific engagement.
“This transaction reflects a shared long-term commitment to patients and a strong alignment in how we translate scientific innovation into meaningful impact,” said Ben Palleiko, chief executive of KalVista. “With Chiesi’s global infrastructure, commercial capabilities and long-term commitment to rare diseases, we are confident in their ability to help expand access to sebetralstat for people living with HAE around the world.”
The transaction has been unanimously approved by both Chiesi’s and KalVista’s boards of directors and is expected to close in the third quarter of 2026, subject to the satisfaction of customary closing conditions.
“We look forward to working with KalVista towards a successful closing of the transaction,” added Mr Chiesi. “From day one, our focus will be on working closely with the HAE community and the scientific community to improve disease management and ensure more patients can benefit from timely, effective treatment.”
News: Italian pharma group Chiesi to buy US peer KalVista for $1.9 billion